← Leaderboards
Meaghan K. McGeary
Yale University
$488,790
Attributed
$488,790
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $107K · FY2020–25$200K$150K$100K$50K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$488,790 · 3
By mechanism
K00$399,974 · 1
F99$66,953 · 1
F31$21,863 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Ruth Halaban$8,123,059
- Harriet M Kluger$18,066,555
- Robert E. Tigelaar$5,277,489
- Richard A Flavell$31,785,615
- Gary V. Desir$8,576,842
Others in their field
Other Emerging Leaders on “New Therapeutic Target”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Kathleen Maletic Neuzil · Emory University$26,258,144
- Priyamvada Acharya · Duke University$26,203,983
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
Research focus
New Therapeutic TargetTumor ImmunityKnock-OutNeoplastic CellTargeted TreatmentTumor GrowthGeneticImmunotherapyMalignant NeoplasmsMethylationResistanceResponseTherapeutic DevelopmentTumorEpigenetic ProcessGene ExpressionImmune ResponseImmunogenicityAnti-Tumor Immune ResponseCancer TypeMelanomaCellsPathway InteractionsBreast
Grant awards (7)
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy$107,050
K00 · FY2025 · CA · contact PI
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy$107,050
K00 · FY2024 · CA · contact PI
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy$94,506
K00 · FY2023 · CA · contact PI
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy$91,368
K00 · FY2022 · CA · contact PI
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy$30,891
F99 · FY2021 · CA · contact PI
Targeting Endogenous Retrovirus Regulation for Augmenting Cancer Immunotherapy$36,062
F99 · FY2020 · CA · contact PI
DNMT3B Control of Melanoma Heterogeneity and Anti-Tumor Immunity$21,863
F31 · FY2020 · CA · contact PI